Ipratropium Bromide Therapy in Respiratory Disease

Introduction to Ipratropium Bromide

• The American Thoracic Society recommends administering ipratropium bromide 500 mcg via nebulizer every 20 minutes for 3 doses, then transitioning to every 4-6 hours until clinical improvement occurs in acute severe asthma or COPD exacerbations 1, 2

Acute Exacerbations of Respiratory Disease

• For acute severe asthma, combining ipratropium 500 mcg with β-agonist (albuterol 2.5-5 mg or terbutaline 5-10 mg) provides additional benefit and should be standard practice 3, 1
• In acute COPD exacerbations, adding ipratropium to β-agonist therapy may be beneficial, despite contradictory evidence, due to its safety profile and potential benefits 1, 2, 3

Maintenance Phase and Chronic Disease Management

• The European Respiratory Society suggests continuing ipratropium 500 mcg every 4-6 hours for 24-48 hours or until peak expiratory flow reaches >75% predicted in the maintenance phase 1, 2
• For chronic bronchitis, administering ipratropium every 6 hours (four times daily) improves cough frequency, severity, and reduces sputum volume 2

Combination Therapy and Nebulization Considerations

• The American College of Chest Physicians states that ipratropium can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour 4
• Combinations of anticholinergics and β-agonists produce additive effects at submaximal doses 4

Safety Considerations and Adverse Effects

• In COPD patients with CO2 retention, air-driven nebulizers should be used to avoid worsening hypercapnia 2
• Oxygen-driven nebulizers are appropriate for acute asthma 3
• Ipratropium has few adverse effects at therapeutic doses, with the most common reported side effect being cough 4